Genenta Secures €20M, Brain Tumor Trial Shows Promising Survival
Genenta Science secured €20 million (approximately $21.9 million) in financing from ENEA Tech and Biomedical (ETB) to support the...
Jon Napitupulu
Pharming Group Announces First Patient Dosed in Phase II Trial for CVID
Pharming Group N.V. has initiated a Phase II clinical trial for leniolisib, targeting common variable immunodeficiency (CVID) patients with...
Savolitinib Shines in HutchMed Phase II Lung Cancer Trial
HUTCHMED announced new data from studies of savolitinib and surufatinib, two compounds it discovered, will be presented at the...
First-of-its-kind Study Shows Monopoint System Utility in IIH Treatment
Route 92 Medical announced positive multicenter study results for their Monopoint system, a novel catheter technology designed for neurovascular...
Tenaya Therapeutics Unveils Breakthrough Cardiac Data at ACC Conference
Tenaya Therapeutics will present new clinical data from the MyPEAK-1 Phase 1b/2 trial of TN-201, a gene therapy for...
Conduit Pharmaceuticals Pipeline Update: AZD1656, AZD5658, & AZD5904
Conduit Pharmaceuticals announced progress in its preclinical and clinical pipeline, including studies for AZD5658 in lupus, Phase IIa trial...
Protara Therapeutics: Choline Deficiency and Liver Injury in Parenteral Support Patients: Encore Presentation of THRIVE-1 Results
Protara Therapeutics announced results from THRIVE-1, a study on choline deficiency and liver injury in patients dependent on parenteral...
Acumen Announces Results for Sabirnetug Formulation Study
Acumen Pharmaceuticals announced positive topline results from a Phase 1 study of its Alzheimer’s drug, sabirnetug. The study compared...
Arbor Biotechnologies Secures $73.9M Series C Funding for Gene Editing
Arbor Biotechnologies secured $73.9 million in Series C funding, led by ARCH Venture Partners and TCGX, to advance its...
Fruquintinib & Sintilimab Trial Meets Primary Endpoint in Advanced RCC
HUTCHMED and Innovent Biologics announced positive top-line results from the FRUSICA-2 Phase II/III trial. The trial investigated fruquintinib combined...